CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Xagena Salute

In pulmonary arterial hypertension ( PAH ), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapie ...


The chymase inhibitor Fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction ( LVD ) after acute m ...


The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs ), compared with use of angiotensin receptor blockers, is associated wit ...


HeartMate 3 Left Ventricular Assist Device ( LVAD ) has received U.S. Food and Drug Administration ( FDA ) clearance as a destination therapy for people living with advanced heart failure. With th ...


In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and mortality. However, several important presentation characte ...


A study has evaluated the influence of anemia on long-term outcomes of patients with acute coronary syndrome undergoing percutaneous coronary intervention ( PCI ). The study included 5668 consecuti ...


The SWEDEHEART ( Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies ) registry routinely collects information on pa ...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany ) has shown that Entresto ( Sacubitril / Valsartan ) can be initiated early and safe ...


Previous studies have shown that low socioeconomic status is associated with a first myocardial infarction, but these findings could not be extended to heart attack survivors to calculate their risk o ...


Mineralocorticoid receptor antagonists ( MRAs ) have been demonstrated to improve outcomes in reduced ejection fraction heart failure ( HFrEF ) patients. However, MRAs added to conventional treatmen ...


Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree t ...


Beta-blockers are the cornerstone of therapy for heart failure; however, the effects of these drugs on the prognosis of patients with concomitant atrial fibrillation remain controversial. The obje ...


There are no studies of mineralocorticoid receptor antagonist ( MRA ) treatment examining outcome in unselected real-life patients with myocardial infarction and heart failure. There is uncertainty ...


A study has assessed the relationship between atrial fibrillation and outcomes in the TOPCAT ( Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist ) trial, to evaluat ...


Since the precise mechanism(s) of cognitive disorders in patients with atrial fibrillation ( AF ) is not fully known, the optimal way to prevent cognitive dysfunction for a given patient remains to be ...